- Stocks
- Healthcare
- NYSE: HAE

Price (delayed)

$70.22

Market cap

$3.58B

P/E Ratio

55.29

Dividend/share

N/A

EPS

$1.27

Enterprise value

$4.19B

Haemonetics is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of

The price to earnings (P/E) is 65% lower than the 5-year quarterly average of 155.8

The company's quick ratio rose by 31% YoY and by 6% QoQ

The equity is up by 11% year-on-year but it has declined by 7% since the previous quarter

The company's gross profit fell by 9% YoY but it rose by 4.5% QoQ

The debt is up by 48% year-on-year and by 11% since the previous quarter

The company's EPS fell by 33% YoY and by 19% QoQ

What are the main financial stats of HAE

Market
Valuations
Earnings

Shares outstanding

51.03M

Market cap

$3.58B

Enterprise value

$4.19B

Price to earnings (P/E)

55.29

Price to book (P/B)

5.28

Price to sales (P/S)

3.96

EV/EBIT

52.81

EV/EBITDA

24.96

EV/Sales

4.64

Revenue

$903.41M

EBIT

$79.42M

EBITDA

$168.02M

Free cash flow

$54.03M

Per share
Balance sheet
Liquidity

EPS

$1.27

Free cash flow per share

$1.06

Book value per share

$13.29

Revenue per share

$17.74

TBVPS

$19.12

Total assets

$1.79B

Total liabilities

$1.12B

Debt

$784.37M

Equity

$677.08M

Working capital

$456.03M

Debt to equity

1.16

Current ratio

3

Quick ratio

1.34

Net debt/EBITDA

3.64

Margins
Efficiency
Dividend

EBITDA margin

18.6%

Gross margin

46%

Net margin

7.1%

Operating margin

8.8%

Return on assets

4.1%

Return on equity

9.2%

Return on invested capital

7.2%

Return on capital employed

5.1%

Return on sales

8.8%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Haemonetics stock price performed over time

Intraday

2.77%

1 week

4.08%

1 month

18.43%

1 year

-16.09%

YTD

-40.87%

QTD

5.37%

How have Haemonetics's revenue and profit performed over time

Revenue

$903.41M

Gross profit

$415.89M

Operating income

$79.42M

Net income

$64.49M

Gross margin

46%

Net margin

7.1%

The operating income is down by 38% year-on-year and by 12% since the previous quarter

The operating margin has contracted by 35% YoY and by 15% from the previous quarter

HAE's net income is down by 32% year-on-year and by 19% since the previous quarter

The net margin is down by 30% year-on-year and by 22% since the previous quarter

What is Haemonetics's growth rate over time

What is Haemonetics stock price valuation

P/E

55.29

P/B

5.28

P/S

3.96

EV/EBIT

52.81

EV/EBITDA

24.96

EV/Sales

4.64

The price to earnings (P/E) is 65% lower than the 5-year quarterly average of 155.8

The company's EPS fell by 33% YoY and by 19% QoQ

The price to book (P/B) is 23% lower than the last 4 quarters average of 6.9 and 18% lower than the 5-year quarterly average of 6.4

The equity is up by 11% year-on-year but it has declined by 7% since the previous quarter

The stock's P/S is 28% less than its last 4 quarters average of 5.5 and 12% less than its 5-year quarterly average of 4.5

The revenue fell by 4.5% YoY but it rose by 3.8% QoQ

How efficient is Haemonetics business performance

The company's return on invested capital fell by 49% YoY and by 20% QoQ

The company's return on assets fell by 45% YoY and by 23% QoQ

HAE's return on equity is down by 43% year-on-year and by 21% since the previous quarter

The company's return on sales fell by 35% YoY and by 15% QoQ

What is HAE's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for HAE.

How did Haemonetics financials performed over time

The total assets is 61% more than the total liabilities

The current ratio has soared by 61% YoY and by 9% from the previous quarter

The total liabilities has grown by 35% YoY and by 2.7% from the previous quarter

The debt is 16% greater than the equity

The debt is up by 48% year-on-year and by 11% since the previous quarter

The debt to equity has grown by 33% YoY and by 20% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.